The company is evaluating whether the drug, which targets cardiac complications, might be used treat patients with other ...

Duchenne muscular dystrophy (DMD) treatment ifetroban led to improvements in measures of heart function in a Phase 2 clinical ...

High-dose treatment with the therapy was found to cause a 3.3% overall improvement in left ventricular ejection fraction.

Cumberland Pharmaceuticals’ Duchenne muscular dystrophy (DMD) drug has improved the amount of blood pumped by the heart, ...

Expert Rev Clin Pharmacol. 2012;5(3):319-336. Aspirin improves clinical outcome in all cardiovascular (CV) syndromes in primary and secondary prevention, including acute events. In high-risk ...

Expert Rev Clin Pharmacol. 2012;5(3):319-336. †There are controversial data concerning prasugrel resistance, and there is a need for larger studies to confirm prasugrel resistance. IPA ...